

FORM PTO-1449(Modified)

AUG 02 1999

Atty. Docket No. R0547/7007(ERG/KA)

SERIAL NO: 09/273,445

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT LIAO et al.

FILING DATE March 19, 1999

GROUP 1646

## U.S. PATENT DOCUMENTS


Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
	*A1	3,983,140	9/28/76	Endo et al.			
	*A2	4,231,938	11/4/80	Monaghan et al.			
	*A3	4,346,227	8/24/82	Terahara et al.			
	*A4	4,351,844	9/28/82	Patchett et al.			
	*A5	4,444,784	4/24/84	Hoffman et al.			
	*A6	4,448,784	5/15/84	Glamkowski et al.			
	*A7	4,450,171	5/22/84	Hoffman et al.			
	*A8	4,499,289	2/12/85	Baran et al.			
	*A9	4,613,610	9/23/86	Wareing			
	*A10	4,686,237	8/11/87	Anderson			
	*A11	4,739,073	4/19/88	Kathawala			
	*A12	4,912,107	3/27/90	Kleinschroth et al.			
	*A13	4,965,200	10/23/90	Chen et al.			
	*A14	5,030,447	8/9/91	Joshi et al.			
	*A15	5,084,482	1/28/92	Hirsch et al.			
	*A16	5,116,870	5/26/92	Smith et al.			
	*A17	5,135,935	8/4/92	Alberts et al.			
	*A18	5,180,589	1/19/93	Joshi et al.			
	*A19	5,273,995	12/28/93	Roth			
	*A20	5,298,497	3/29/94	Tschollar et al.			
	*A21	5,354,772	10/11/94	Kathawala			
	*A22	5,470,832	11/28/95	Gibbs et al.			
	*A23	5,475,029	12/12/95	Bradfute et al.			
	*A24	5,514,696	5/7/96	Murugesan et al.			
	*A25	5,519,035	5/21/96	Maiese et al.			
	*A26	5,530,001	6/25/96	Nakajima et al.			
	*A27	5,591,772	1/7/97	Lane et al.			
	*A28	5,602,098	2/11/97	Sehti et al.			
	*A29	5,612,359	3/18/97	Murugesan			
	*A30	5,622,985	4/22/97	Olukotun et al.			
	*A31	5,723,456	3/3/98	Jirousek et al.			
	*A32	5,756,453	5/26/98	Vedder et al.			
	A33	5,565,448	10/15/96	Nambi et al.			
	A34	5,545,636	8/13/96	Heath, Jr. et al.			
	A35	5,593,971	1/14/97	Tschollar et al.			

RECEIVED

AUG 04 1999

TECH CENTER 1600/2900

FORM PTO-1449(Modified)	Atty. Docket No. R0547/7007(ERG/KA)	SERIAL NO. 09/273,445
	APPLICANT LIAO et al.	
	FILING DATE March 19, 1999	GROUP 1646



## FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Pub Class	Translation Yes No
✓	*B1	JP 09183797 A	7/15/97			

## OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

✓	*C1	Blauw, G.J., et al., "Stroke, Statins, and Cholesterol: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials With HMG-CoA Reductase Inhibitors" <i>Stroke</i> 28(5):946-950 (1997)
	*C2	<i>Boston Globe</i> "Statins Found to Cut Risk of Stroke: Cholesterol Drugs Curbed Death Rate" (7/23/97)
	*C3	Bult, H., "Nitric Oxide and Atherosclerosis: Possible Implications for Therapy" <i>Mol. Med. Today</i> 2(12):510-518 (1996), Abstract
	*C4	Byington, R.P., et al., "Reduction in Cardiovascular Events During Pravastatin Therapy: Pooled Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention Program" <i>Circulation</i> 92(9):2419-2425 (1995)
	*C5	Casino, P.R., et al., "The Role of Nitric Oxide in Endothelium-Dependent Vasodilation of Hypercholesterolemic Patients" <i>Circulation</i> 88(6):2541-2547 (1993), Abstract
	*C6	Cooke, J.P., et al., "Nitric Oxide Synthase: Role in the Genesis of Vascular Disease" <i>Annu. Rev. Med.</i> 48:489-509 (1997), Abstract
	*C7	Crouse, J.R., et al., "Reductase Inhibitor Monotherapy and Stroke Prevention" <i>Arch. Intern. Med.</i> 157:1305-1310 (1997)
	*C8	Dusting, G.J., "Nitric Oxide in Coronary Artery Disease: Roles in Atherosclerosis, Myocardial Reperfusion and Heart Failure" <i>EXS</i> 76:33-55 (1996), Abstract
	*C9	Giaid, A., et al., "Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension" <i>New Eng. J. Med.</i> 333(4):214-221 (1995)
	*C10	Hebert, P.R., et al., "Cholesterol-Lowering Reduces Risks of Stroke and Total Mortality" <i>Circulation</i> 94 Suppl 1:I-744 (1996) Abstract 4351
	*C11	Hebert, P.R., et al., "Cholesterol Lowering and the Risk of Stroke" <i>Arch. Intern. Med.</i> 156:214-215 (1996)
	*C12	Hislop, A., et al., "Endothelial Nitric Oxide Synthase in Hypoxic Newborn Porcine Pulmonary Vessels" <i>Arch Dis Child Fetal Neonatal Ed.</i> , 77(1):F16-22 (July 1997), Abstract
	*C13	Jessup, W., "Oxidized Lipoproteins and Nitric Oxide" <i>Curr. Opin. Lipidol.</i> 7(5):274-280 (1996), Abstract
	*C14	Laufs, U., et al., "Neue Erkenntnisse über die Wirkung von HMG-CoA-Reduktase-Hemmern" <i>Dtsch. Med. Wschr.</i> 122:1255-1259 (1997)
	*C15	Macdonald, P., et al., "The Role of Nitric Oxide in Heart Failure. Potential for Pharmacological Intervention" <i>Drugs Aging</i> 8(6):452-458 (1996), Abstract
	*C16	Martinez-Riera, A., et al., "Primary Prevention of Stroke" <i>New Engl. J. Med.</i> 334(17):1138-1139 (1996)
✓	*C17	Massoudy, P. et al., "Cardioprotection by Cyclosporine A in Experimental Ischemia and Reperfusion--Evidence for a Nitric Oxide-Dependent Mechanism Mediated by Endothelin" <i>Mol. Cell Cardio.</i> 29, 535-544 (1997)

FORM PTO-1449(Modified)	Atty. Docket No. R0547/7007(ERG/KA)	SERIAL NO. 09/273,445
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT LIAO et al.	
	FILING DATE March 19, 1999	GROUP 1646


✓	* C18	Munzel, T., et al., "The Physiology and Pathophysiology of the Nitric Oxide/Superoxide System" Herz 22(3):158-172 (1997), Abstract
	* C19	O' Driscoll, G., et al., "Simvastatin, an HMG-Coenzyme A Reductase Inhibitor, Improves Endothelial Function within 1 Month" Circulation 95(5):1126-1131 (1997), Abstract
	* C20	Rector, T.S., et al., "Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Oral L-Arginine in Patients with Heart Failure" Circulation 93(12):2135-2141 (1996), Abstract
	* C21	Sacks, F.M., et al., "The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels" New Engl. J. Med. 335(14):1001-1009 (1996)verage Cholesterol Levels"
	* C22	Samdani, A.F., et al., "Nitric Oxide Synthase in Models of Focal Ischemia" Stroke 28(6):1283-1288 (1997), Abstract
	* C23	Sartor, G., et al., "Simvastatin Treatment of Hypercholesterolemia in Patients with Insulin Dependent Diabetes Mellitus" Int. J. Clin. Pharmacol. Ther. 33(1):3-6 (1995), Abstract
✓	* C24	Stroes, E., et al., "Tetrahydrobiopterin Restores Endothelial Function in Hypercholesterolemia" J. Clin. Invest. 99(1):41-46 (1997), Abstract
✓	* C25	Warshafsky, S., et al., "Efficacy of HMG-CoA Reductase Inhibitors For Prevention of Stroke" Abstract

## OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

✓	* C26	Wolf, A., et al., "Dietary L-Arginine Supplementation Normalizes Platelet Aggregation in Hypercholesterolemic Humans" J. Am. Coll. Cardiol. 29(3):479-485 (1997), Abstract
✓	* C27	Yokoyama, M., et al., "Regulation of Nitric Oxide Synthase Gene Expression by Cytokines" J. Card. Fail. 2(4 Suppl):S179-S185 (1996), Abstract

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/132,848, filed August 11, 1998, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER 	DATE CONSIDERED <u>11/28/03</u>
--	---------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL FORM PTO-1449 (Revised)</b>		ATTY. DOCKET NO. R0457/7007	SERIAL NO. 09/273,445
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT			
MAY 18 2000		APPLICANT LIAO	
		FILING DATE March 19, 1999	GROUP 1646

### U.S. PATENT DOCUMENTS

Exam Init	Ref ID	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
/	A36*	5,968,983	10/19/99	Kaesemeyer	514	564	04/10/97
/	A37*	5,945,452	08/31/99	Cooke <i>et al.</i>	514	564	02/07/97
/	A38*	5,891,459	04/06/99	Cooke <i>et al.</i>	424	439	11/09/95
/	A39*	5,830,910	11/03/98	Mattson	514	411	10/23/95
/	A40*	5,767,160	06/16/98	Kaesemeyer	514	565	08/05/96
/	A41*	5,543,430	08/06/96	Kaesemeyer	514	565	10/05/94
/	A42*	5,519,035	5/21/96	Maiese, et al.	514	309	07/02/93
/	A43*	5,428,070	06/27/95	Cooke <i>et al.</i>	514	557	06/11/93
/	A44*	5,385,940	01/31/95	Moskowitz	514	565	11/05/92

### FOREIGN PATENT DOCUMENTS


		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes	No
/	B2*	WO 00/03746	1/2000	The Brigham and Women's Hospital	—	—		
/	B3*	WO 99/47153	9/1999	The Brigham and Women's Hospital	—	—		
/	B4*	WO 99/18952	4/1999	The Brigham and Women's Hospital	—	—		
/	B5*	WO98/34626	13/08/98	Medical University of South Carolina	—	—		
/	B6*	EP0671171A1	13/09/95	Bristol-Meyers Squibb Company	—	—		

### OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)


/	C28*	Laufs et al., "Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation Of Endothelial Nitric Oxide Synthase," <i>Journal of Biological Chemistry</i> , Vol. 272, No. 50, pp. 31725-9, December 1997.
/	C29*	Laufs et al., "Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase," <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 37, pp. 24266-24271, September 11, 1998.
/	C30*	Lopez-Ongil et al., "Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells," <i>American Journal of Physiology</i> , Vol. 271, No. 3, pp. H1072-8, September 1996.
/	C31*	Ohara et al., "Regulation of Endothelial Constitutive Nitric Oxide Synthase by Protein Kinase C," <i>Hypertension</i> , Vol. 25, No. 3, pp. 415-420, March 1995.
/	C32*	Stroes, et al., "Cyclosporin A Increases Nitric Oxide Activity In Vivo", <i>Hypertension</i> , 29:2 (1997) pp. 570-575
/	C33*	Yano et al., "Involvement of rho p21 in Cyclic Strain-Induced Tyrosine Phosphorylation of Focal Adhesion Kinase (pp125-FAK), Morphological Changes and Migration of Endothelial Cells," <i>Biochemical and Biophysical Research Communications</i> , Vol. 224, pp. 508-515, (1996)
/	C34	Copy of International Search Report for PCT/US99/06185
/	C35	Copy of International Search Report for PCT/US99/15827

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/132,848, filed August 11, 1998, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER 	DATE CONSIDERED 11/28/03
--	--------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/273,445	ATTY. DOCKET NO.: R0547/7007
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		FILING DATE: March 19, 1999	
		APPLICANT: James K. Liao, et al.	
		GROUP ART UNIT: 1617	EXAMINER: E. J. Webman
Sheet	1	of	4

RECEIVED  
 MAR 7 2002  
 TECH. LIT. 1600/290

**U.S. PATENT DOCUMENTS**

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YY
		Number	Kind Code		
K	A47	H1286		Eisman, et al.	02/01/94
	A48	4,920,109		Onishi, et al.	04/24/90
	A49	4,920,111		Onishi, et al.	04/24/90
	A50	4,920,113		Onishi, et al.	04/24/90
	A51	4,929,437		Tobert	05/29/90
	A52	4,933,165		Brown	06/12/90
	A53	5,025,003		Biller	06/18/91
	A54	5,082,650		Folkers, et al.	01/21/92
	A55	5,084,482		Hirsch, et al.	01/28/92
	A56	5,130,333		Pan, et al.	07/14/92
	A57	5,140,012		McGovern, et al.	08/18/92
	A58	5,182,298		Helms, et al.	01/26/93
	A59	5,190,970		Pan, et al.	03/02/93
	A60	5,211,947		Brannan, et al.	05/18/93
	A61	5,254,544		Biller, et al.	10/19/93
	A62	5,256,689		Chiang	10/26/93
	A63	5,260,305		Dennick	11/09/93
	A64	5,260,332		Dufresne	11/09/93
	A65	5,262,435		Joshua, et al.	11/16/93
	A66	5,273,969		Biller, et al.	12/28/93
	A67	5,283,256		Dufresne, et al.	02/01/94
	A68	5,294,627		Arison, et al.	03/15/94
	A69	5,302,604		Byrne, et al.	04/12/94
	A70	5,312,814		Biller, et al.	05/17/94
	A71	5,316,765		Folkers, et al.	05/31/94
	A72	5,317,031		MacConnell, et al.	05/31/94
	A73	5,340,573		Garnick	08/23/94
	A74	5,369,125		Berger, et al.	11/29/94
	A75	5,395,846		Morris, et al.	03/07/95
	A76	5,441,946		Pauls, et al.	08/15/95
	A77	5,447,922		Lawrence, et al.	09/05/95
	A78	5,451,596		Ullrich, et al.	09/19/95
A79	5,453,429		Bliem, et al.	09/26/95	
A80	5,455,260		Groneberg, et al.	10/03/95	
A81	5,470,845		Magnin, et al.	11/28/95	
A82	5,506,262		Burk, et al.	04/09/96	



FORM PTO-1449/A and B (Modified)

APPLICATION NO.: 09/273,445

ATTY. DOCKET NO.: R0547/7007

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

FILING DATE: March 19, 1999

APPLICANT: James K. Liao, et al.

GROUP ART UNIT: 1617

EXAMINER: E. S. Webman

Sheet 2 of 4

**RECEIVED**  
MAR 27 2002  
TECH. UNIT 1800/2900

K	A83	5,534,532	Groneberg, et al.	07/09/96
	A84	5,556,844	Reichert, et al.	09/17/96
	A85	5,561,143	Groneberg, et al.	10/01/96
	A86	5,563,128	Pauls, et al.	10/08/96
	A87	5,595,734	Mikulski, et al.	01/21/97
	A88	5,596,020	Morris, et al.	01/21/97
	A89	5,605,930	Samid	02/25/97
	A90	5,616,570	Lange III, et al.	04/01/97
	A91	5,616,593	Patel, et al.	04/01/97
	A92	5,622,987	Brunavs, et al.	04/22/97
	A93	5,633,285	Martin	05/27/97
	A94	5,634,895	Igo, et al.	06/03/97
	A95	5,661,145	Davis	08/26/97
	A96	5,663,186	Nelson, et al.	09/02/97
	A97	5,663,187	Nelson, et al.	09/02/97
	A98	5,674,488	Reich	10/07/97
	A99	5,681,278	Igo, et al.	10/28/97
	A100	5,691,375	Behounek, et al.	11/25/97
	A101	5,693,337	Suzuki, et al.	12/02/97
	A102	5,712,396	Magnin, et al.	01/27/98
	A103	5,730,992	Savion, et al.	03/24/98
	A104	5,733,558	Breton, et al.	03/31/98
	A105	5,744,467	McKittrick, et al.	04/28/98
	A106	5,756,470	Yumibe, et al.	05/26/98
	A107	5,798,375	Tsujita, et al.	08/25/98
	A108	5,807,834	Morehouse	09/15/98
	A109	5,846,966	Rosenblum, et al.	12/08/98
	A110	5,847,008	Doebber, et al.	12/08/98
	A111	5,859,051	Adams, et al.	01/12/99
	A112	5,861,399	Seed, et al.	01/19/99
	A113	5,883,109	Gregg, et al.	03/16/99
	A114	5,900,433	Igo, et al.	05/04/99
	A115	5,902,805	Breton, et al.	05/11/99
	A116	5,912,019	Singh	06/15/99
	A117	5,945,097	Cutler	08/31/99
	A118	5,990,110	Firestone	11/23/99
	A119	6,020,382	Doebber, et al.	02/01/00
✓	A120	6,022,887	Gasper, et al.	02/08/00
✓	A121	6,043,265	Murugesan, et al.	03/28/00



FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/273,445		ATTY. DOCKET NO.: R0547/7007	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		FILING DATE: March 19, 1999			
		APPLICANT: James K. Liao, et al.			
		GROUP ART UNIT: 1617		EXAMINER: E. J. Webman	
Sheet	3	of	4		

RECEIVED  
 MAR 07 2002  
 TECH. UNIT 1800/2900

✓	A122	6,057,339		Gregg	05/02/00
	A123	6,066,653		Gregg, et al.	05/23/00
	A124	6,077,849		Liu, et al.	06/20/00
	A125	6,080,422		Williams	06/27/00
	A126	6,080,778		Yanker, et al.	06/27/00
	A127	6,080,779		Gasper, et al.	06/27/00
	A128	6,083,985		Yonemoto, et al.	07/04/00
	A129	6,090,830		Myers, et al.	07/18/00
	A130	6,090,836		Adams, et al.	07/18/00
	A131	6,090,839		Adams, et al.	07/18/00
	A132	6,093,719		Bocan	07/25/00
	A133	6,103,742		Ikeda, et al.	08/15/00
	A134	6,121,283		Chang, et al.	09/19/00
	A135	6,121,295		Ikeda, et al.	09/19/00
	A136	6,121,319		Somers	09/19/00
	A137	6,124,309		Bocan	09/26/00
	A138	6,126,947		Savion, et al.	10/03/00
	A139	6,130,214		Lohray, et al.	10/10/00
	A140	6,143,755		Bocan	11/07/00
	A141	6,143,770		Lane, et al.	11/07/00
	A142	6,147,109		Liao, et al.	11/14/00
	A143	6,149,948		Vincent	11/21/00
	A144	6,153,629		Hoie	11/28/00
	A145	6,159,993		Seed, et al.	12/12/00
	A146	6,159,997		Tsujita, et al.	12/12/00
	A147	6,160,000		Adams, et al.	12/12/00
	A148	6,169,100	B1	Ikeda	01/02/01
	A149	6,174,874	B1	Wang, et al.	01/16/01
	A150	6,180,597	B1	Liao	01/30/01
	A151	6,180,660	B1	Whitney, et al.	01/30/01
✓	A152	6,180,680	B1	Cavazza	01/30/01
✓	A153	6,190,894	B1	Thronfeldt, et al.	02/20/01

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
✓	B8	EP	0 422 895		Glaxo Group Limited	04/17/91	
	B9	EP	0 424 929		Takeda Chemical Industries	05/02/91	
✓	B10	EP	0 461 548		E.R. Squibb & Sons, Inc.	12/18/91	



FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

APPLICATION NO.: 09/273,445

ATTY. DOCKET NO.: R05477007

FILING DATE: March 19, 1999

APPLICANT: James K. Liao, et al.

GROUP ART UNIT: 1617

EXAMINER: E. J. Wagoner

Sheet

4

of

4

✓	B11	EP	0 529 854		Ortho Pharmaceutical	03/03/93	
✓	B12	WO	93/12123		British Bio-Technology Limited	06/24/93	
✓	B13	WO	95/06470		Merck & Co., Inc.	03/09/95	
✓	B14	WO	95/13063	A1	Merck & Co., Inc.	05/18/95	
✓	B15	WO	98/11896	A1	Merck & Co., Inc.	03/26/98	
✓	B16	WO	98/47518	A1	European Lab. for Molecular Biology	10/29/98	
✓	B17	WO	99/15159	A2	Nova Molecular, Inc.	04/01/99	
✓	B18	WO	00/28981	A2	Nymox Corporation	05/25/00	

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
✓	C36	Wilhelmsen, "Practical Guidelines for Drug Therapy after Myocardial Infarction" Drugs, Vol. 38, No. 6, pp. 1000-1007 (1989).	
✓	C37	Jones, "Lovastatin and Simvastatin Prevention Studies," The American Journal of Cardiology, Vol. 66, pp. 39B-43 (1990).	
✓	C38	Brown, et al., "Regression of Coronary Artery Diseases as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B," The New England Journal of Medicine, Vol. 323, No. 19, pp. 1289-1298 (1990).	
✓	C39	Sacks, et al., "Rationale and Design of a Secondary Prevention Trial of Lowering Normal Plasma Cholesterol Levels After Acute Myocardial Infarction: the Cholesterol and Recurrent Events Trial (CARE)," The American Journal of Cardiology, Vol. 68, pp. 1436-1445 (1991).	
✓	C40	The West of Scotland Coronary Prevention Study Group, "A Coronary Primary Prevention Study of Scottish Men Aged 45-64 Years: Trial Design," Journal of Clinical Epidemiology, Vol. 45, No. 8, pp. 849-860 (1992).	
✓	C41	Schmidt, et al., "Elevated lipoprotein(a) is lowered by a cholesterol synthesis inhibitor in a normocholesterolaemic patient with mature myocardial infarction," Blood Coagulation and Fibrinolysis, Vol 4, pp. 173-175 (1993).	
✓	C42	Zhukova, et al., "Long-term experience with lovastatin treatment in patients with coronary heart disease and hyperlipoproteinaemia type II," European Heart Journal, Vol 13, Supp. B, pp. 7-10 (1992).	
✓	C43	Pearson, et al., "The Rapid Reduction in Cardiac Events with Lipid-Lowering Therapy: Mechanisms and Implications," The American Journal of Cardiology, Vol. 72, pp. 1072-1073 (1993).	
✓	C44	The Pravastatin Multinational Study Group for Cardiac Risk Patients, "Effects of Pravastatin in Patients with Serum Total Cholesterol Levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) Plus Two Additional Atherosclerotic Risk Factors," The American Journal of Cardiology, Vol. 72, pp. 1031-1037 (1993).	
✓	C45	Scandinavian Simvastatin Survival Study Group, "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)," The Lancet, Vol. 344, pp. 1383-1389 (1994).	

EXAMINER

DATE CONSIDERED

11/28/03

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

589964.1



APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF  
COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

ENI-028BCP

SERIAL NO.

09/273,445

LIST OF PUBLICATIONS CITED BY APPLICANT  
(Use several sheets if necessary)

APPLICANT

James K. Liao, et al.

FILING DATE

March 19, 1999

GROUP

1617

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	US 5,674,893		Behounek et al.			
	A2	US 6,369,103 B1		Behounek et al.			
	A3	US 6,165,975		Adams et al.			
	A4	US 5,217,997		Levere et al.			
	A5	US 6,117,872		Maxwell et al.			
	A6	US 6,239,172 B1		Kaesemeyer			
	A7	US 6,425,881 B1		Kaesemeyer			
	A8	US 6,465,516 B1		Kaesemeyer			
	A9	US 2003/0032616 A1		Moskowitz et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	A10	WO 00/66328		no copy			

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)


Examiner

Date Considered

11/28/03

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.